---
title: "Gene‑editing breakthroughs face price and access challenges"
summary: "Gene‑editing offers hope for thousands of rare diseases, but the drugs are expensive and hard to develop. Most new gene therapies cost around $2 bn and only a small share of illnesses get approved treatments. Big pharma focuses on profitable cancers, leaving rare disorders under‑funded. The UK’s NHS would need public money and manufacturing to make therapies affordable, treating them like essential services rather than luxury items."
category: "Public Health Care"
section: "Opinion"
imageUrl: "https://media.guim.co.uk/07b4358bf657bc1620a2bee05ba696f0c6930fdb/487_0_4297_3437/500.jpg"
publishedAt: "2025-12-21T17:25:03Z"
guardianId: "commentisfree/2025/dec/21/the-guardian-view-on-gene-editing-breakthroughs-need-a-new-social-contract"
---

Gene‑editing offers hope for thousands of rare diseases, but the drugs are expensive and hard to develop. Most new gene therapies cost around $2 bn and only a small share of illnesses get approved treatments. Big pharma focuses on profitable cancers, leaving rare disorders under‑funded. The UK’s NHS would need public money and manufacturing to make therapies affordable, treating them like essential services rather than luxury items.
